LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Prothena Corp PLC

Fechado

SetorSaúde

5.39 6.52

Visão Geral

Variação de preço das ações

24h

Atual

Mín

5.01

Máximo

5.43

Indicadores-chave

By Trading Economics

Rendimento

-2.2M

-60M

Vendas

705K

2.8M

EPS

-1.12

Margem de lucro

-2,128.536

Funcionários

163

EBITDA

-682K

-65M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+380.04% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-495M

251M

Abertura anterior

-1.13

Fecho anterior

5.39

Sentimento de Notícias

By Acuity

50%

50%

167 / 380 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Prothena Corp PLC Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de jun. de 2025, 20:45 UTC

Ganhos

Broadcom 2Q Sales Climb on Booming AI Demand

5 de jun. de 2025, 23:45 UTC

Conversa de Mercado

Nikkei May Decline as Caution Over U.S. Economy Continues -- Market Talk

5 de jun. de 2025, 23:44 UTC

Conversa de Mercado

Gold Edges Higher on Weak U.S. Data -- Market Talk

5 de jun. de 2025, 23:30 UTC

Conversa de Mercado

NZME Cost Cuts Can Cushion Effect of Weak Market -- Market Talk

5 de jun. de 2025, 21:32 UTC

Ganhos

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

5 de jun. de 2025, 20:45 UTC

Ganhos

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 de jun. de 2025, 20:24 UTC

Ganhos

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 de jun. de 2025, 20:15 UTC

Ganhos

Broadcom 2Q Cont Ops EPS $1.03 >AVGO

5 de jun. de 2025, 20:15 UTC

Ganhos

Broadcom 2Q Rev $15B >AVGO

5 de jun. de 2025, 20:15 UTC

Ganhos

Broadcom 2Q Net $4.97B >AVGO

5 de jun. de 2025, 20:15 UTC

Ganhos

Broadcom 2Q Adj EPS $1.58 >AVGO

5 de jun. de 2025, 20:15 UTC

Ganhos

Broadcom 2Q EPS $1.03 >AVGO

5 de jun. de 2025, 20:15 UTC

Ganhos

Broadcom Sees 3Q Rev $15.8B >AVGO

5 de jun. de 2025, 20:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Constellation Energy: Transaction Is Expected to Close in the 4Q >CEG

5 de jun. de 2025, 20:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Constellation Energy: Calpine Deal Clears Texas Regulatory Review

5 de jun. de 2025, 20:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Constellation Energy: With Approval From PUCT Secured, Transaction Awaits Clearance From NY State Public Service Commission, Federal Energy Regulatory Commission and DOJ >CEG

5 de jun. de 2025, 19:22 UTC

Conversa de Mercado

Oil Futures Resume Upward Moves -- Market Talk

5 de jun. de 2025, 19:00 UTC

Conversa de Mercado

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

5 de jun. de 2025, 18:32 UTC

Conversa de Mercado

Gold Slips After Trump-Xi Call -- Market Talk

5 de jun. de 2025, 18:26 UTC

Ganhos

These Stocks Are Moving the Most Today: Broadcom, Tesla, Circle, Brown-Forman, MongoDB, Planet Labs, ChargePoint, Ciena, and More -- Barrons.com

5 de jun. de 2025, 18:06 UTC

Conversa de Mercado

Transpacific Ship Freight Rates Spike on China Tariff Truce -- Market Talk

5 de jun. de 2025, 16:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Vallourec Completes The Acquisition Of Thermotite Do Brasil >VK.FR

5 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

5 de jun. de 2025, 16:18 UTC

Conversa de Mercado

U.S. Natural Gas Market Shrugs Off Big Storage Build -- Market Talk

5 de jun. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

5 de jun. de 2025, 16:12 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

5 de jun. de 2025, 16:12 UTC

Conversa de Mercado

Copper Prices Rise on Positive Signals From Trump on China Trade Talks -- Market Talk

5 de jun. de 2025, 16:03 UTC

Conversa de Mercado

U.S. Diesel, Gasoline Futures Pick Back Up -- Market Talk

5 de jun. de 2025, 15:49 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

Comparação entre Pares

Variação de preço

Prothena Corp PLC Previsão

Preço-alvo

By TipRanks

380.04% parte superior

Previsão para 12 meses

Média 24.29 USD  380.04%

Máximo 81 USD

Mínimo 4 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Prothena Corp PLC - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

9 ratings

4

Comprar

4

Manter

1

Vender

Pontuação Técnica

By Trading Central

N/A / 7.35Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Very Strong Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

167 / 380 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.